Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Q4 2022 Earnings Call Transcript
Aldeyra Therapeutics reported 2022 financial results, highlighting FDA acceptance of two new drug applications: Reproxalap for dry eye disease and ADX-2191 for primary vitreoretinal lymphoma. The company is advancing its RASP modulation platform, with ADX-629 in Phase 2 trials for various conditions. ADX-2191, targeting ocular lymphoma, has a PDUFA date of June 21, 2023. Aldeyra's cash position supports operations into late 2024, with a net loss of $62.0 million in 2022.
Reference News
Aldeyra Therapeutics reported 2022 financial results, highlighting FDA acceptance of two new drug applications: Reproxalap for dry eye disease and ADX-2191 for primary vitreoretinal lymphoma. The company is advancing its RASP modulation platform, with ADX-629 in Phase 2 trials for various conditions. ADX-2191, targeting ocular lymphoma, has a PDUFA date of June 21, 2023. Aldeyra's cash position supports operations into late 2024, with a net loss of $62.0 million in 2022.